Emerging retatrutide, a combined-action treatment targeting simultaneously GLP-1 and GIP receptors, is sparking considerable interest within the medical community. Initial clinical studies have revealed significant losses in physical size and gains in metabolic markers for individuals with obesity . Scientists believe this novel approach may mark a